论文部分内容阅读
作者在治疗几种小儿难治性癫痫用当前抗癫痫药物(AED)时,对附加口服 Vigabatrin(γ-乙烯基氨酪酸,GVG)的疗效及安全性进行了单盲安慰剂对照研究。资料与方法 61例患者列入本研究,年龄12～229个月(平均108个月),癫痫持续时间6～197个月(平均74个月)。全部患者对当前可获得的AED多重治疗均无效。平均联合 AED 1.93种,GVG 以500mg片剂供应。每日剂量分早、晚2次口服。研究由开始
The authors conducted a single-blind, placebo-controlled study of the efficacy and safety of additional oral Vigabatrin (G-VG) in the treatment of several pediatric refractory epilepsy with current AEDs. Materials and Methods 61 patients aged 12 to 229 months (mean 108 months) and epileptic duration 6 to 197 months (mean 74 months) were enrolled in this study. All patients are not eligible for multiple currently available AED treatments. An average of 1.93 AEDs were combined and GVG was supplied as 500 mg tablets. Daily doses of morning and evening 2 times orally. Research started